Published in Oncotarget on September 29, 2015
EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling. Oncotarget (2016) 0.86
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget (2016) 0.76
Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics (2016) 0.76
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer (2016) 0.76
Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. Oncotarget (2016) 0.75
Advances in sarcoma diagnostics and treatment. Oncotarget (2016) 0.75
Precision medicine driven by cancer systems biology. Cancer Metastasis Rev (2017) 0.75
EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res (2016) 0.75
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers (Basel) (2015) 0.75
EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma. Oncotarget (2016) 0.75
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Cancer Biol Ther (2016) 0.75
Regulation of cancer epigenomes with a histone-binding synthetic transcription factor. NPJ Genom Med (2017) 0.75
Genome-wide mapping of in vivo protein-DNA interactions. Science (2007) 64.92
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res (2015) 14.81
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
The Polycomb complex PRC2 and its mark in life. Nature (2011) 11.97
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev (2005) 8.95
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Extraction, purification and analysis of histones. Nat Protoc (2007) 6.25
DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol (2005) 5.02
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol (1998) 3.61
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A (2012) 3.22
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. Nucleic Acids Res (2010) 2.47
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol (2012) 2.17
ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl) (2009) 2.08
Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem (2006) 1.99
The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle (2012) 1.98
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer (2010) 1.93
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res (1999) 1.88
Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell (2013) 1.85
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade. J Immunol (2009) 1.70
TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol (1998) 1.63
Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem (2011) 1.49
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem (2012) 1.38
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res (2011) 1.30
Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res (2011) 1.27
mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther (2005) 1.20
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun (2015) 1.15
Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. PLoS One (2013) 1.13
Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain. PLoS One (2013) 1.08
In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opin Drug Discov (2008) 1.03
Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells. Biochem Biophys Res Commun (2010) 1.02
A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol (2007) 1.01
Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim Biophys Acta (2013) 1.00
Epigenetic regulation of skin: focus on the Polycomb complex. Cell Mol Life Sci (2012) 0.99
Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol (2007) 0.97
Gene expression profiling indicate role of ER stress in miR-23a~27a~24-2 cluster induced apoptosis in HEK293T cells. RNA Biol (2011) 0.97
p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res (2000) 0.97
Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. Cell Death Dis (2014) 0.96
Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis (2014) 0.96
Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model. Oncogene (2014) 0.94
MDA-7/IL-24: multifunctional cancer killing cytokine. Adv Exp Med Biol (2014) 0.93
EZH2: an emerging role in melanoma biology and strategies for targeted therapy. Pigment Cell Melanoma Res (2014) 0.87
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth. Oncotarget (2015) 0.82
Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo. Tumour Biol (2013) 0.78
Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell Melanoma Res (2013) 0.82
Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget (2015) 0.79
EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res (2016) 0.75
A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Proteomics Clin Appl (2017) 0.75